Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure

Hematology

Volumn 10, Issue 3, 2005, Pages 255-259

  Lim, Lay Cheng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Acquired; Chronic renal disease; Erythropoietin; Neutralizing antibody

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AUTOIMMUNE DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DISEASE ASSOCIATION; ERYTHEMA INFECTIOSUM; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; PATHOGENESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; TREATMENT RESPONSE; IMMUNOLOGY; PARVOVIRUS; VIRUS INFECTION;

AUTOIMMUNE DISEASES; EPOETIN ALFA; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; RED-CELL APLASIA, PURE;

EID: 25144432914     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330400026154     Document Type: Review

References (33)

1. Kaznelson P. Zür Enstehung der Blutt Plättchen. Verh Ditsch Ges Inn Med 1979;34:557.
2. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
3. McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992;12:162-169.
4. Montagnac R, Boffa GA, Schillinger F, Guillaumie J. Sensibilisation à l'erythropoiétine humaine recombinante chez une hémodialysée. Presse Med 1992;21:84-85.
5. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997;47:331-335.
6. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. NY, New York: Marcel Dekker; 1993.
7. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996;335:523-524.
8. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987;262:12059-12076.
9. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Macdougall IC, Macleod A, Horl WH, Wiecek A, Cameron S. Erythropoiesis- stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant 2004;19:288-293.
10. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Ressert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-1408.
11. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-1722.
12. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-583.
13. Kaufman JS. Subcutaneous erythropoietin therapy: Efficacy and economic implications. Am J Kidney Dis 1998;32:S147-S151.
14. Ramsay CR, Campbell MK, Cantarovich D, Catto G, Cody J, Daly C, Delcroix C, Edward N, Grimshaw JM, van Hamersvelt HW, Henderson IS, Khan IH, Koene RA, Papadimitrou M, Ritz E, Tsakiris D, MacLeod AM. Evaluation of clinical guidelines for the management of endstage renal disease in Europe: The EU BIOMED 1 study. Nephrol Dial Transplant 2000;15:1394-1398.
15. Grant E. Epoietin and pure red cell aplasia. DrugInform 2002;23(5):31-36 [http://www.ukmicentral.nhs.uk/therapeu/ drg_inf/drg23-05.pdf5].
16. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004;15:398-406.
17. Casadevall N. Antibodies against rHuEPO: Native and recombinant. Nephrol Dial Transplant 2002;17(Suppl. 5):42-47.
18. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet 2004; 363:1768-1771.
19. Quint L, Casadevall N, Giraudier S. Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 2004;124:842.
20. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-1586, author reply 1584-6.
21. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl. 2):ii34-ii36.
22. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004;96:c88-c95.
23. Eckardt KU, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003;18:865-869.
24. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002;13:2381-2383.
25. Snanoudj R, Beaudreuil S, Arzouk N, Jacq D, Casadevall N, Charpentier B, Durrbach A. Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation. Am J Transplant 2004;4:274-277.
26. Summers SA, Matijevic A, Almond MK. Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 2004;19:2137-2139.
27. Lim LC, Krishna VS, How GF, Lou HX, Ng HJ, Chuah C, Loh Y, Choong HL. Acquired pure red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure - incidence and outcomes. Blood 2003;102, Abstract 1821.
28. Schellekens H. Bioequivalence and immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462.
29. Klaus GGB, Humphrey JH. The fate of antigens. In: Lachmann PJ, Peters K, Rosen FS, Walport WJ, editors. Clinical aspects of immunology. Boston, MA: Blackwell Scientific; 1993. p 107-126.
30. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity? Pharm Res 2003;20:1903-1907.
31. Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk. J Am Soc Nephrol 2004;15:2728-2734.
32. Summary of PRCA case reports. Johnson & Johnson News. 2004. [http://www.jnj.com/news/jnj_news/1021024_095632. htm]
33. Trontell A. Expecting the unexpected - drug safety, pharmacovigilance, and the prepared mind. N Engl J Med 2004;351:1385-1387.